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parameter more easily aff ected by the 
avoidance of myograph-assisted tech-
nique) was the determining factor in the 
increased M:L ratio values.
Nevertheless, the reduction observed 
in the M:L ratio was about 15%, reason-
ably close to the reduction of about 20% 
observed in other studies.3 Unfortu-
nately, the baseline (before-treatment) 
M:L ratio was significantly higher in 
the losartan-treated group than in the 
amlodipine-treated group (see Table 2 
in Gómez-Garre et al.5), and although 
it may be argued that the differences 
between losartan and amlodipine are 
even more remarkable because the 
former was applied to patients with more 
severe cases, comparison of the eff ects of 
two treatments on a given variable is dif-
fi cult when the starting characteristics of 
the variable are not similar.
As noted by the authors5, CTGF, 
TGFβ, and collagen IV expressions 
were not reduced by losartan treatment; 
rather, this drug prevented the increase 
observed with amlodipine treatment. 
Interestingly, the expression of collagen 
III was reduced by both treatment sched-
ules.
The villain role of amlodipine is, at 
least to me, somewhat unexpected, as in 
vitro studies have shown that amlodipine 
inhibits proliferation of vascular smooth 
muscle cells,8 downregulates expression 
of collagens, and increases collagenase 
type IV activity.9 Inasmuch as the sponta-
neous evolution of cytokine expression in 
the resistance arterioles of patients with 
well-controlled mild essential hyperten-
sion is unknown (it would be unethical 
to withhold antihypertensive treatment 
for 1 year), the conclusion that losartan 
prevented, or that amlodipine caused, an 
increment in cytokine expression is open 
to question. Nevertheless, this important 
study discloses discordant eff ects of two 
well-accepted treatments of essential 
hypertension on the structural changes 
of resistance arterioles. Taken together 
with previously reported investigations 
and recent clinical studies,10 these results 
would speak in favor of the use of AT1 
receptor blockers in this condition and 
underline the need of further studies 
to defi ne the eff ects of antihypertensive 
drugs on arterial remodeling.
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ACE inhibition and glomerular 
repair: restructuring or 
regeneration?
JA Joles1, B Braam1 and MC Verhaar2
In this issue of Kidney International, Andrea Remuzzi et al. convincingly 
demonstrate glomerular repair in spontaneous renal disease by ACE 
inhibition. These findings provoke questions about how ACE inhibition 
(or AT1R blockade) can on the one hand actually repair some diseased 
kidneys while on the other interfering with normal renal development 
or the recovery of other diseased kidneys.
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Suppression of angiotensin formation 
by angiotensin-converting enzyme 
(ACE) inhibitors or blockade of the 
angiotensin II receptor type 1 (AT1R) 
can induce regression of injury in 
patients with non-diabetic or diabetic 
proteinuric nephropathy.1 Regression 
of glomerular injury by ACE inhibition 
or AT1R blockade has also been shown 
in rodents, both in spontaneous mod-
els of renal disease such as in aging and 
in the Munich Wistar Frömter (MWF) 
rat,2 and in diverse experimental models 
including puromycin aminonucl eoside 
nephropathy, chronic nitric oxide 
synthase inhibition, and five-sixths 
nephrectomy.3 In this issue, Dr. Andrea 
Remuzzi and his colleagues go one step 
further and convincingly demonstrate 
glomerular repair.4
Remuzzi et al. found that the extent 
of glomerular damage in MWF rats at 
60 weeks of age, aft er 10 weeks of ACE 
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inhibition starting at 50 weeks of age, 
was signifi cantly less than that in 50-
week-old MWF rats. Proteinuria fell 
and renal function remained constant. 
Presumably, arterial pressure also fell to 
normal levels during ACE inhibition,2 
although this was not confirmed in 
the old rats in the present study. Age-
matched MWF rats showed progressive 
proteinuria and increased serum creati-
nine over this 10-week period, and, at 
60 weeks, much more glomeruloscle-
rosis expressed as volume of the tuft . 
Complete analysis of individual tuft s 
led to the conclusion that in this model 
ACE inhibition truly appears to eff ect 
glomerular repair. Th is contrasts with 
our fi ndings in fawn-hooded hyperten-
sive (FHH) rats, in which withdrawal 
of ACE inhibition revealed that further 
development of previously established 
glomerular damage could not be pre-
vented despite lowering of glomerular 
capillary pressure.5
Interestingly, glomerular repair in 
MWF rats happens without any decrease 
in glomerular tuft  volume, despite the 
fact that systemic arterial and glomeru-
lar capillary pressures are known to fall 
in this model during ACE inhibition.2 
Th is is at variance with the fall in mean 
glomerular tuft  volume observed in rats 
with subtotal nephrectomy (SNX) in 
which ACE inhibition was initiated aft er 
8 weeks.3 In the latter study, by Adam-
czak et al., tuft  volume was lower aft er 
12 weeks of SNX in combination with 
ACE inhibition for the last 4 weeks, than 
aft er 8 weeks of SNX. However, tuft  vol-
ume aft er SNX and late ACE inhibition 
remained higher than in sham controls,3 
despite the fact that ACE inhibition is 
known to reduce glomerular capillary 
pressure in this model. Th us, ACE inhi-
bition can support regression of glomer-
ular damage both with and without 
eff ects on glomerular tuft  volume.
Remuzzi et al.4 used elegant three-
dimensional reconstruction of indi-
vidual glomerular capillary tuft s based 
on serial sections of 15 to 20 glomeruli 
per rat with a total of 100 glomeruli per 
group. In these aged MWF rats, this 
striking technique revealed that aft er 
10 weeks of ACE inhibition, at 60 weeks 
of age, more than 20% of glomeruli were 
completely free of sclerosis, whereas at 
50 weeks of age practically no glomeruli 
had been free of some degree of scle-
rosis. This observation strongly sug-
gests that space previously occupied by 
glomerulosclerosis was now occupied 
by new capillary tissue. Th e question is: 
How does this happen?
Th e three-dimensional reconstruc-
tion technique does not provide infor-
mation on glomerular components at 
the cellular level. Th is prohibits insight 
into repair mechanisms. Th e authors 
document a reduction in glomerular 
staining of TGFβ and α-smooth mus-
cle actin, which suggests that ACE 
inhibition reduced glomerular matrix. 
Indeed, it is well known that angio-
tensin acts as a mitogen on mesangial 
cells. However, repair restricted to the 
mesangial compartment cannot fully 
explain tuft  repair. Th ere may also be 
eff ects on podocyte number, but their 
quantitative contribution is unknown 
in situations where injury is reversible. 
Improved endothelial-cell function and 
enhanced angiogenesis might explain 
a benefi cial eff ect of ACE inhibition; 
however, whether such an eff ect of ACE 
inhibition6 may be extrapolated to the 
glomerular endothelium or glomeru-
lar capillary repair (angiogenesis) 
is unknown.
ACE inhibitors may also aff ect pro-
genitor cells of the bone marrow. In 
various experimental models, bone mar-
row progenitor cells have been shown to 
diff erentiate into glomerular endothe-
lial cells, mesangial cells,7 and podo-
cytes and to contribute to glomerular 
repair. Angiotensin II has been shown 
to accelerate endothelial progenitor 
cell senescence via increased oxida-
tive stress.8 Both ACE inhibition and 
AT1R blockade enhanced the number 
of regenerative endothelial progenitor 
cells in patients at increased cardiovas-
cular risk.9
Eff ects of AT1R blockade and ACE 
inhibition on vascular structure in the 
kidney, either on locally residing cells 
(angiogenesis) or on progenitor cells 
(vasculogenesis), are not restricted to 
the glomerulus. In the developing kid-
ney, loss of signaling by angiotensin 
gives rise to vascular hypertrophy. 
Th is has been observed in mice lacking 
angiotensinogen, ACE, or AT1Rs, and 
in normotensive and hypertensive rats 
aft er ACE inhibition or AT1R block-
ade.10 It is interesting in this regard 
that, in mice with selective ablation of 
renin-expressing juxtaglomerular cells, 
no abnormalities in renal arteriolar 
dimensions were observed, which con-
trasts with fi ndings in all of the other 
mice with angiotensinogen, ACE or 
AT1R gene deletion.11 Th us, inhibition 
of the actions of angiotensin has been 
associated with vascular hypertrophy. 
Because renin levels will be high under 
these conditions, renin may be a pri-
mary factor in the pathogenesis of this 
hypertrophy. Th ere appear to be direct 
interactions between renin and vascular 
endothelial growth factor in glomerular 
angiogenesis and renal arteriogenesis.12 
Similar vascular changes were observed 
in the kidneys of Fischer donor rats aft er 
transplantation into Lewis recipient rats 
treated with ACE inhibition or AT1R 
blockade.13 Th us, angiotensin II appears 
to be crucial not only in embryonic 
renal development but also in certain 
phases of adult renal repair. Interest-
ingly, specifi c adult repair mechanisms 
mimic, to some extent, the development 
of the glomerular tuft  during ontogeny. 
Indeed, angiotensin II infusion acceler-
ated renal repair in the early phase of 
experimental glomerulonephritis.14
Th e complexity of repair is illustrated 
by the fi nding of a marked, progressive 
increase in the number of glomerular 
capillaries and endothelial cells in par-
allel with glomerular hypertrophy in 
the SNX model, without much change 
in capillary density per unit volume of 
tuft , or in endothelial-cell number per 
capillary. Th is suggests that, at least in 
SNX, increased endothelial-cell num-
bers and hence capillary hyperplasia 
parallel glomerular injury. Th is process 
appeared to be reversed by ACE inhibi-
tion.3 Th us, new questions are spawned 
by these studies on glomerular repair: 
Is the local mitotic index reduced, or is 
there less recruitment of bone marrow-
derived stem cells? How does ACE inhi-
bition under certain conditions increase 
but under others decrease glomeru-
lar endothelial-cell number? Such a 
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dichotomy has recently been observed 
in other vascular beds with ACE inhibi-
tion in type 1 diabetic mice.15 Perhaps, 
in glomerular injury, inhibition of 
endothelial-cell contact — or, in renal 
development, incomplete establishment 
of a contiguous endothelial-cell layer — 
dictates the actions of angiotensin and 
hence ACE inhibition.
Hopefully, this Commentary will 
stimulate the reader to wonder about 
how ACE inhibition (or AT1R block-
ade) can on the one hand actually repair 
some diseased kidneys but on the other 
hand interfere with normal renal devel-
opment or the recovery of other dis-
eased kidneys. Certainly studies such as 
those by Dr. Remuzzi and his colleagues 
should not be dismissed as being about 
‘just another rat with proteinuria that’s 
cured by ACE inhibition’.
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Non-Pseudomonas Gram-negative 
peritonitis
AK Jain1 and PG Blake2
Non-Pseudomonas Gram-negative organisms account for over 10% 
of cases of peritoneal dialysis-associated peritonitis. The key findings 
from a paper by Szeto et al. are discussed and compared with those 
from previous publications. This type of peritonitis has a high rate of 
catheter removal and technique failure. Results may be better with 
more aggressive antibiotic treatment. Other developments in the field 
are reviewed.
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Th e superiority of the well-done ran-
domized controlled trial over all other 
forms of clinical studies is widely 
accepted and understood. However, the 
relative rarity of such trials in the dialy-
sis literature is also well recognized. 
Th ere are many areas of dialysis practice 
where randomized trials have not been 
carried out or are not feasible. Th ere-
fore, the continuing importance of other 
forms of clinical investigations should 
not be forgotten. Th is includes the old-
fashioned retrospective review of clini-
cal experience with a large number of 
cases of a given condition. Th e article 
by Szeto et al.1 in this issue is an excel-
lent example.
Th e topic is peritoneal dialysis (PD)-
related peritonitis due to Enterobac-
teriaceae organisms. Th e investigators 
review a decade’s experience in a single 
large Hong Kong center with a total of 
210 cases. This is the largest reported 
series to date of cases of what is some-
times termed non-Pseudomonas Gram-
negative (NPGN) peritonitis.2 Th e paper 
provides a wealth of important and 
helpful clinical observations, and, taken 
together with two earlier papers from the 
Unites States, it enhances our knowledge 
of this important condition.2,3
Peritonitis remains the single big-
gest cause of technique failure in PD. 
Advances over the past two decades 
in connectology and in Staphylococ-
cus aureus prophylaxis have led to 
impressive decreases in the rates of 
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